As organised pharma retail channel consolidates in India with the entry of big players, a recent Credit Suisse report highlights that volume-based discounts may increase and end up disrupting the branded generic drugs market.
The report says that if substitution of medicines (where chemists can replace the doctor's prescription with a generic drug) is allowed in India, then firms which have high exposure to chronic therapeutic drugs will be impacted more as the trade channel becomes more consolidated. Firms like Torrent Pharmaceutical, Sun Pharma, Lupin, and Cipla would be impacted ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
Copyrights © 2020 Business Standard Private Ltd. All rights reserved.
